HeyJaredSusan Reckling
- Indexed articles, last 90 days
- 5
- Latest publication
- Sep 2, 2026
- Outlet visibility, for Cancer Therapy Advisor
- Top 5M sites
- Earliest in this view
- Aug 26, 2026
Latest articles
Clinical Practice Outcomes Support Use of Darolutamide With LMAs in nmCRPC (opens the original)
Read excerpt
Clinical practice supports darolutamide plus androgen-deprivation therapy (ADT) as a “standard-of-care treatment option” for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), including those receiving concomitant lipid-modifying agents (LMAs). These findings, which were published in JAMA Network Open, are consistent with the results of the phase 3 ARAMIS trial (NCT02200614), study researchers reported. The nonrandomized, observational DAROL IA4 trial included 799 patient
Breast-Conserving Surgery Viable for Some Multiple Ipsilateral Breast Cancers - Oncology Nurse Advisor (opens the original)
Read excerpt
Breast-conserving surgery — the treatment of choice for unisite breast cancers — appears to be viable for carefully selected patients with multiple ipsilateral breast cancers (MIBCs), according to research published in the European Journal of Surgical Oncology. Patients with unisite breast cancers and those with MIBCs were found to have a similar risk profile for local recurrence and breast cancer-specific survival when treated with breast-conserving surgery, study researchers reported. Long-ter
Clinical Practice Outcomes Support Use of Darolutamide With LMAs in nmCRPC - Oncology Nurse Advisor (opens the original)
Read excerpt
Clinical practice supports darolutamide plus androgen-deprivation therapy (ADT) as a “standard-of-care treatment option” for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), including those receiving concomitant lipid-modifying agents (LMAs). These findings, which were published in JAMA Network Open, are consistent with the results of the phase 3 ARAMIS trial (NCT02200614), study researchers reported. The nonrandomized, observational DAROL IA4 trial included 799 patient
Clinical Practice Outcomes Support Use of Darolutamide With LMAs in nmCRPC (opens the original)
Read excerpt
Clinical practice supports darolutamide plus androgen-deprivation therapy (ADT) as a “standard-of-care treatment option” for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), including those receiving concomitant lipid-modifying agents (LMAs). These findings, which were published in JAMA Network Open, are consistent with the results of the phase 3 ARAMIS trial (NCT02200614), study researchers reported. The nonrandomized, observational DAROL IA4 trial included 799 patient
Breast-Conserving Surgery Viable for Some Multiple Ipsilateral Breast Cancers (opens the original)
Read excerpt
Breast-conserving surgery — the treatment of choice for unisite breast cancers — appears to be viable for carefully selected patients with multiple ipsilateral breast cancers (MIBCs), according to research published in the European Journal of Surgical Oncology. Patients with unisite breast cancers and those with MIBCs were found to have a similar risk profile for local recurrence and breast cancer-specific survival when treated with breast-conserving surgery, study researchers reported. Long-ter
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Cancer Therapy Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.